BR0214611A - Antagonistas vii de receptor ccr-3 - Google Patents

Antagonistas vii de receptor ccr-3

Info

Publication number
BR0214611A
BR0214611A BR0214611-8A BR0214611A BR0214611A BR 0214611 A BR0214611 A BR 0214611A BR 0214611 A BR0214611 A BR 0214611A BR 0214611 A BR0214611 A BR 0214611A
Authority
BR
Brazil
Prior art keywords
ccr
receptor antagonists
vii
compounds
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
BR0214611-8A
Other languages
English (en)
Inventor
Daisy Joe Du Bois
Beihan Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann-La Roche AG
Hoffmann-La Roche Inc
Original Assignee
F Hoffmann-La Roche AG
Hoffmann-La Roche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann-La Roche AG, Hoffmann-La Roche Inc filed Critical F Hoffmann-La Roche AG
Publication of BR0214611A publication Critical patent/BR0214611A/pt
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

"ANTAGONISTAS VII DE RECEPTOR CCR-3". A presente invenção refere-se a compostos de Fórmula (I) onde R^ 1^-R^ 4^, A, D e L são como definidos no relatório descritivo. Os compostos são úteis como antagonistas de receptor CCR-3, e por isso, podem ser usados para tratamento de doenças mediadas por CCR-3.
BR0214611-8A 2001-11-30 2002-11-20 Antagonistas vii de receptor ccr-3 Withdrawn BR0214611A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33481901P 2001-11-30 2001-11-30
PCT/EP2002/012997 WO2003045917A2 (en) 2001-11-30 2002-11-20 Ccr-3 receptor antagonists vii

Publications (1)

Publication Number Publication Date
BR0214611A true BR0214611A (pt) 2004-09-14

Family

ID=23308965

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214611-8A Withdrawn BR0214611A (pt) 2001-11-30 2002-11-20 Antagonistas vii de receptor ccr-3

Country Status (16)

Country Link
US (1) US7019007B2 (pt)
EP (1) EP1453804B1 (pt)
JP (1) JP2005518364A (pt)
KR (1) KR100579352B1 (pt)
CN (1) CN1296356C (pt)
AR (1) AR037586A1 (pt)
AT (1) ATE370932T1 (pt)
AU (1) AU2002356694A1 (pt)
BR (1) BR0214611A (pt)
CA (1) CA2468402A1 (pt)
DE (1) DE60222015T2 (pt)
ES (1) ES2291539T3 (pt)
MX (1) MXPA04004980A (pt)
PL (1) PL373275A1 (pt)
RU (1) RU2004120065A (pt)
WO (1) WO2003045917A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1296978A2 (en) * 2000-06-30 2003-04-02 Bristol-Myers Squibb Company N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
US7491737B2 (en) * 2002-10-30 2009-02-17 Merck & Co., Inc. Heterarylpiperidine modulators of chemokine receptor activity
CA2767153A1 (en) * 2003-02-20 2004-09-02 Encysive Pharmaceuticals Inc. Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists
IN2006CH00378A (en) * 2003-06-30 2007-05-11 Sumitomo Chemical Co Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst
US7541468B2 (en) * 2004-06-10 2009-06-02 Bristol-Myers Squibb Company Process of preparing N-ureidoalkyl-piperidines
US8883791B2 (en) * 2010-09-29 2014-11-11 Intervet Inc. N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB953005A (en) * 1961-02-24 1964-03-18 Soc Ind Fab Antibiotiques Sifa Substituted n-phenylethyl-n-phenyl-piperazines
US5051423A (en) 1988-07-13 1991-09-24 Schering Ag Derivatized alkanolamines as cardiovascular agents
HU206337B (en) * 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
JPH0592921A (ja) * 1991-05-17 1993-04-16 Yamanouchi Pharmaceut Co Ltd シクロヘキシルアルキルアミド および 該化合物を有効成分とするタキキニン抑制剤
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
CA2306811A1 (en) * 1997-10-14 1999-04-22 Yoshiyuki Aoki Piperazine compounds and medicinal use thereof
AU3126700A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2000035451A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1158980B1 (en) 1998-12-18 2005-08-24 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CN1206219C (zh) * 1998-12-18 2005-06-15 布里斯托尔-迈尔斯斯奎布药品公司 作为趋化因子受体活性调节剂的n－脲基烷基－哌啶化合物
AU2482100A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6331541B1 (en) * 1998-12-18 2001-12-18 Soo S. Ko N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1205473A4 (en) * 1999-07-28 2004-06-16 Daiichi Radioisotope Lab VESAMICOL PIPERAZINE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING THESE DERIVATIVES
GB0012240D0 (en) * 2000-05-19 2000-07-12 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
WO2003045917B1 (en) 2003-12-04
DE60222015D1 (de) 2007-10-04
US7019007B2 (en) 2006-03-28
CA2468402A1 (en) 2003-06-05
WO2003045917A3 (en) 2003-10-09
JP2005518364A (ja) 2005-06-23
MXPA04004980A (es) 2004-08-11
KR20040062663A (ko) 2004-07-07
WO2003045917A2 (en) 2003-06-05
US20030153578A1 (en) 2003-08-14
ATE370932T1 (de) 2007-09-15
CN1599721A (zh) 2005-03-23
RU2004120065A (ru) 2005-05-27
DE60222015T2 (de) 2008-06-05
EP1453804B1 (en) 2007-08-22
CN1296356C (zh) 2007-01-24
AU2002356694A1 (en) 2003-06-10
KR100579352B1 (ko) 2006-05-12
ES2291539T3 (es) 2008-03-01
PL373275A1 (en) 2005-08-22
EP1453804A2 (en) 2004-09-08
AR037586A1 (es) 2004-11-17

Similar Documents

Publication Publication Date Title
TNSN02012A1 (fr) Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant
ATE388951T1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
CO5601019A2 (es) Polimorfo del clohidrato de la [6,7-bis(2-metoxi-etoxi)-quinazolin-4-il]-(3-etinil-fenil) amina
ATE551059T1 (de) Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
MY135841A (en) Novel benzodioxoles
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
NO20055649L (no) Substituert dihydrokinazolin med antiviale egenskaper
TW200634012A (en) 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
DK1501507T3 (da) Tetrahydropyranyl-cyclopentyl-tertrahydropyridopyrindin-modulatorer af kemokin-receptor-aktivitet
ATE368034T1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
BRPI0407913A (pt) antagonistas receptores de ccr-3
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
TW200519096A (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
BRPI0409580A (pt) compostos de quinazolina
WO2003106450A8 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
YU75603A (sh) Dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja
ATE367380T1 (de) Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate
BR0214582A (pt) Derivados de piperazina para uso como antagonista do receptor ccr-3 no tratamento de asma
DE60233350D1 (de) IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES
ATE363474T1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
SE0200844D0 (sv) Chemical compounds
BR0214611A (pt) Antagonistas vii de receptor ccr-3
SE0200843D0 (sv) Chemical compounds
DE602004005881D1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
BRPI0415767A (pt) antagonistas de receptor de ccr-3

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2064 DE 27/07/2010.